Silence Therapeutics PLC Additional listing and Total Voting Rights (3693O)
February 08 2021 - 10:28AM
UK Regulatory
TIDMSLN
RNS Number : 3693O
Silence Therapeutics PLC
08 February 2021
Additional listing and Total Voting Rights
February 8, 2021
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN
("Silence" or "the Company"), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced that it has issued
and allotted 16,928 new ordinary shares of 5p each ("New Ordinary
Shares") following the exercise of share options under the Employee
Share Option Scheme.
Application will be made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM. Admission is
expected to be effective on February 12, 2021. The New Ordinary
Shares shall rank pari passu with the existing ordinary shares in
the Company.
The total number of ordinary shares of 5p each in issue,
following admission of the New Ordinary Shares, will be 83,332,187.
The Company holds no shares in Treasury. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR & Corporate Communications
ir@silence-therapeutics.com
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary messenger RNAi GOLD(TM) (GalNAc
Oligonucleotide Discovery) Platform can be used to create siRNAs
that precisely target and silence disease-associated genes in the
liver, which represents a substantial opportunity. Silence's wholly
owned product candidates include SLN360 designed to address the
high and prevalent unmet medical need in reducing cardiovascular
risk in people born with high levels of lipoprotein(a) and SLN124
designed to address iron loading anemias. Silence also maintains
ongoing research and development collaborations with AstraZeneca,
Mallinckrodt Pharmaceuticals, and Takeda, among others. For more
information, please visit https://www.silence-therapeutics.com/
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSDKFBBABKDOBK
(END) Dow Jones Newswires
February 08, 2021 11:28 ET (16:28 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024